Xlife Sciences AG: Collaboration with the University of MarburgEQS
Im Artikel erwähnte Wertpapiere: Xlife Sciences AG
Inventum Genetics GmbH and Universität Marburg agree on a collaboration
The cooperation between Inventum Genetics and the University of Marburg is a long-term agreement. In a first projects, new therapeutic targets and biomarkers for oncological, neurodegenerative and age-related diseases are be identified using the latest genetic and molecular biological processes. Oliver R. Baumann, CEO der Xlife Sciences, is delighted with the additional prospects for drug development: "All common diseases, like the majority of all oncological, neurodegenerative and age-associated diseases, are multifactorial in cause, not just caused by a singular genetic defect. Rather, multifactorial diseases are characterized by the fact that they are based on (exogenous) environmental factors and (endogenous) genetic risk factors. In this particular project with the University of Marburg, cellular disease mechanisms of multifactorial diseases are to be elucidated. For this purpose, cells are stimulated with exogenous risk factors. It will then be examined how the cells react to it depending on their genetic makeup."
The agreement with the Philipps-University of Marburg gives the university the right to pursue the results achieved in its own research and to industrialize them, provided Inventum Genetics does not use the results itself. In this case, Inventum Genetics would benefit from the royalties generated by the university.
About the Philipps-University Marburg
About Inventum Genetics GmbH
About Xlife Sciences AG
For media inquiries:
For scientific inquiries:
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Research/Technology
22.06.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Frankfurt, Munich|
|EQS News ID:||1210373|
|End of News||DGAP Media|